Lung Cancer Dispatch
4.6K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Postop Opioid Use Tied to NSCLC Recurrence

Postop Opioid Use Tied to NSCLC Recurrence | Lung Cancer Dispatch | Scoop.it

"Non-small cell lung cancer (NSCLC) patients who experienced disease recurrence half a decade after surgery received a significantly higher dose of opioids postoperatively, researchers said here.


"In a retrospective study among patients treated for early-stage NSCLC, recurrence occurred in 26 who received a mean dose of 232 mg of opioids in the 96 hours after surgery compared with 124 mg of opioids administered to the 73 patients in whom there was no recurrence in 5 years (P=0.020), reported Dermot Maher, MD,from Cedars-Sinai Medical Center in Los Angeles, and colleagues."

Cancer Commons's insight:

MedPage Today  |  May 4, 2014

more...
No comment yet.
Rescooped by Cancer Commons from Prostate Cancer Dispatch
Scoop.it!

GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain

"Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex® for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication.


"FDA's Fast Track program facilitates the development of drugs intended to treat serious or life‑threatening conditions and that have the potential to address unmet medical needs. A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval."

Cancer Commons's insight:

Nasdaq  |  Apr 28, 2014

more...
Cancer Commons's curator insight, April 29, 2014 6:04 PM

Nasdaq  |  Apr 28, 2014

Cancer Commons's curator insight, April 29, 2014 6:05 PM

Nasdaq  |  Apr 28, 2014